BridgeBio Pharma, Inc.
BBIOBiotechnology
$70.73−0.13%As of Oct 29vs prior close
- Market cap
- $13.8B
- P/E (TTM)
- –
- From 52W high
- −21.56%
- EPS (LTM)
- -$3.04
- Revenue (LTM)
- $945.5M
- Net margin
- -62.62%
Nomior Score
58
Steady ProfileTop 31% of the scored universe
Growth74
Quality56
Value53
Momentum50
Resilience43
Growth
+52.09%revenue a year over 6 fiscal years
FY19 $40.6MLTM $945.5M
Connections
Revenue to profitQ3 FY26
The operating loss was 3% of revenue, narrower by 117 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $353.2 million
- Net loss
- $83.0 million
Revenue rose sharply from the prior-year quarter, led by growth in Attruby net product sales and a one-time sales milestone from Bayer. The company still reported a loss from operations, though it was much smaller than a year earlier, as commercialization and development spending increased. The release emphasizes new real-world evidence for acoramidis and several upcoming regulatory decisions for new launches.
Who owns it
1fund, 2 tracked portfolios